immix Data: 95% Overall Response Rate in Multiple Myeloma

 

• 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-off
• 90% overall response rate observed in relapsed/refractory multiple myeloma at the therapeutic dose including patients with, and without prior BCMA-targeted therapy
• Class-Leading Response Rate in BCMA-exposed patients (frequently excluded from BCMA CAR-T clinical trials) has the potential to meet an important market need
• ImmixBio plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201
• The expected primary endpoints for NXC-201 in relapsed/refractory multiple myeloma are overall response rate and duration of response

https://www.globenewswire.com/news-release/2023/10/02/2752722/0/en/Immix-Biopharma-Announces-72-Patient-NXC-201-Clinical-Data-at-the-IMS-20th-Annual-Meeting-95-Overall-Response-Rate-in-Multiple-Myeloma.html